FMRI measurement of CNS responses to naloxone infusion and subsequent mild noxious thermal stimuli in healthy volunteers

Journal of Neurophysiology

Volumn 91, Issue 6, 2004, Pages 2723-2733

  Borras, M C ^a   Becerra, L ^a   Ploghaus, A ^a   Gostic, J M ^a   DaSilva, A ^a   Gonzalez, R G ^a   Borsook, D ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Descartes Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MU OPIATE RECEPTOR; MU OPIATE RECEPTOR ANTAGONIST; NALOXONE; OPIATE; SODIUM CHLORIDE;

ADULT; ANALGESIA; ARTICLE; BRAIN CORTEX; BRAIN FUNCTION; BRAIN REGION; CENTRAL NERVOUS SYSTEM FUNCTION; CINGULATE GYRUS; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG INFUSION; ENTORHINAL CORTEX; HIPPOCAMPUS; HUMAN; HUMAN EXPERIMENT; IMAGE ANALYSIS; IMAGING SYSTEM; INSULA; MALE; NERVE CONDUCTION; NEUROIMAGING; NOCICEPTIVE STIMULATION; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ORBITAL CORTEX; PREFRONTAL CORTEX; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIGNAL DETECTION; THALAMUS; THERMAL STIMULATION;

ADULT; BRAIN; CENTRAL NERVOUS SYSTEM; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; HEAT; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NALOXONE; PAIN MEASUREMENT;

EID: 2442624322     PISSN: 00223077     EISSN: None     Source Type: Journal    
DOI: 10.1152/jn.00249.2003     Document Type: Article

References (79)

1. Adler LJ, Gyulai FE, Diehl DJ, Mintun MA, Winter PM, and Firestone LL. Regional brain activity changes associated with fentanyl analgesia elucidated by positron emission tomography. Anesth Analg 84: 120-126, 1997.
2. Amanzio M and Benedetti F. Neuropharmacological dissection of placebo analgesia: expectation-activated opioid systems versus conditioning-activated specific subsystems. J Neurosci 19: 484-494, 1999.
3. Bain GT and Kornetsky C. Naloxone attenuation of the effect of cocaine on rewarding brain stimulation. Life Sci 40: 1119-1125, 1987.
4. Becerra LR, Breiter HC, Stojanovic M, Fishman S, Edwards A, Comite AR, Gonzalez RG, and Borsook D. Human brain activation under controlled thermal stimulation and habituation to noxious heat: an fMRI study. Magn Reson Med: 1044-1057, 1999.
5. Becerra L, Breiter HC, Wise R, Gonzalez RG, and Borsook D. Reward circuitry activation by noxious thermal stimuli. Neuron 32: 927-946, 2001a.
6. Becerra L, Gonzalez RG, Breiter HC, and Borsook D. Activation in nucleus accumbens following pain and analgesia. Soc Neurosci Abstr 27: 507, 2001b.
7. Bechara A and van der Kooy D. Opposite motivational effects of endogenous opioids in brain and periphery. Nature 314: 533-534, 1985.
8. Bencherif B, Fuchs PN, Sheth R, Dannals RF, Campbell JN, and Frost JJ Pain activation of human supraspinal opioid pathways as demonstrated by [11C]-carfentanil and positron emission tomography (PET). Pain 99: 589-598, 2002.
9. Benjamin D, Grant ER, and Pohorecky LA. Naltrexone reverses ethanol-induced dopamine release in the nucleus accumbens in awake, freely mov
10. Bodnar RJ and Hadjimarkou MM. Endogenous opiates and behavior: 2002. Peptides 24: 1241-1302, 2003.
11. Borsook D, Falkowski O, Rosen H, Comb M, and Hyman SE. Opioids modulate stress-induced proenkephalin gene expression in the hypothalamus of transgenic mice: a model of endogenous opioid gene regulation by exogenous opioids. J Neurosci 14: 7261-7271, 1994.
12. Britton KT and Southerland S. Naloxone blocks "anxiolytic" effects of neuropeptide Y. Peptides 22: 607-612, 2001.
13. Buchsbaum MS, Davis GC, Naber D, and Pickar D. Pain enhances naloxone-induced hyperalgesia in humans as assessed by somatosensory evoked potentials. Psychopharmacology 79: 99-103, 1983.
14. Carr KD. The physiology of opiate hedonic effects and the role of opioids in motivated behavior. Adv Alcohol Subst Abuse 3: 5-18, 1984.
15. Davis GC, Buchsbaum MS, van Kammen DP, and Bunney WE Jr. Analgesia to pain stimuli in schizophrenics and its reversal by naltrexone. Psychiatry Res 1: 61-69, 1979.
16. Danilov A, Sandrini G, Antonaci F, Capararo M, Alfonsi E, and Nappi G. Bilateral sympathetic skin response following nociceptive stimulation: study in healthy individuals. Funct Neurol 9: 141-151, 1994.
17. Delfs JM, Kong H, Mestek A, Chen Y, Yu L, Reisine T, and Chesselet MF. Expression of mu opioid receptor mRNA in rat brain: an in situ hybridization study at the single cell level. J Comp Neurol 345: 46-68, 1994.
18. Drolet G, Dumont EC, Gosselin I, Klinkead R, Laforest S, and Trottier JF. Role of endogenous opioid system in the regulation of the stress response. Prog Neuropsychopharmacol Biol Psychiatry 25: 729-741, 2001.
19. Eichenberger GC, Ribeiro SJ, Osaki MY, Maruoka RY, Resende GC, Castellan-Baldan L, Correa SA, Da Silva LA, and Coimbra NC. Neuroanatomical and psychopharmacological evidence for interaction between opioid and GABAergic neural pathways in the modulation of fear and defense elicited by electrical and chemical stimulation of the deep layers of the superior colliculus and dorsal periaqueductal gray matter. Neuropharmacology 42: 48-59, 2002.
20. Emrich HM. A possible role of opioid substances in depression Adv Biochem Psychopharmacol 32: 77-84, 1982.
21. Emrich HM. Endorphins in psychiatry. Psychiatr Dev 2: 97-114, 1984.
22. Fields H. Pain modulation and the action of analgesic medications. Ann Neurol 35, Suppl: S42-45, 1994.
23. Firestone LL, Gyulai F, Mintun M, Adler LJ, Urso K, and Winter PM. Human brain activity response to fentanyl imaged by positron emission tomography. Anesth Analg 82: 1247-1251, 1996.
24. Grevert P and Goldstein A. Effects of naloxone on experimentally induced ischemic pain and on mood in human subjects Proc Natl Acad Sci USA 74: 1291-1294, 1977.
25. Grevert P and Goldstein A. Endorphins: naloxone fails to alter experimental pain or mood in humans. Science 199: 1093-1095, 1978.
26. Grevert P, Albert LH, and Goldstein A. Partial antagonism of placebo analgesia by naloxone. Pain 16: 129-143, 1983.
27. Haefely W. Antagonists of benzodiazepines. Encephale 9: 143B-150B, 1983.
28. Hagen MC, Zald DH, Thornton TA, and Pardo JV. Somatosensory processing in the human inferior prefrontal cortex. J Neurophysiol 88: 1400-1406, 2002.
29. Heishman SJ, Stitzer ML, Bigelow GE, and Liebson IA. Acute opioid physical dependence in humans: effect of varying the morphine-naloxone interval. I. J Pharmacol Exp Ther 250: 485-491, 1989.
30. Herman BH and Panksepp J. Effects of morphine and naloxone on separation distress and approach attachment: evidence for opiate mediation of social affect. Pharmacol Biochem Behav 9: 213-220, 1978.
31. Hollerman JR, Tremblay L, and Schultz W. Involvement of basal ganglia and orbitofrontal cortex in goal-directed behavior. Prog Brain Res 126: 193-215, 2000.
32. Jacob JJ and Michaud GM. Reversal by naloxone of the effects of morphine on the unanesthetized dog. Arch Int Pharmacodyn Ther 222: 322-340, 1976.
33. Kieffer BL. Recent advances in molecular recognition and signal transduction of active peptides: receptors for opioid peptides. Cell Mol Neurobiol 15: 615-635, 1995.
34. Kjelstrup KG, Tuvnes FA, Steffenach HA, Murison R, Moser EI, and Moser MB. Reduced fear expression after lesions of the ventral hippocampus. Proc Natl Acad Sci USA 99: 10825-10830, 2002.
35. Kornetsky C. Action of opioid drugs on the brain-reward system. NIDA Res Monogr 147: 33-52, 1995.
36. Kurvers HA, Tangelder GJ, De Mey JG, Slaaf DW, Beuk RJ, van den Wildenberg FA, Kitslaar PJ, Reneman RS, and Jacobs MJ. Skin blood flow abnormalities in a rat model of neuropathic pain: result of decreased sympathetic vasoconstrictor outflow? J Auton Nerv Syst 63: 19-29, 1997.
37. Laulin JP, Larcher A, Celerier E, Le Moal M, and Simonnet G. Long-lasting increased pain sensitivity in rat following exposure to heroin for the first time Eur J Neurosci 10: 782-785, 1998.
38. Li X and Clark JD. Hyperalgesia during opioid abstinence: mediation by glutamate and substance p. Anesth Analg 95: 979-984, 2002.
39. Lowe AS, Williams SC, Symms MR, Stolerman IP, and Shoaib M. Functional magnetic resonance neuroimaging of drug dependence: naloxone-precipitated morphine withdrawal. Neuroimage 17: 902-910, 2002.
40. Mansour A, Fox CA, Burke S, Meng F, Thompson RC, Akil H, and Watson SJ, Mu, delta, and kappa opioid receptor mRNA expression in the rat CNS: an in situ hybridization study. J Comp Neurol 350: 412-438, 1994.
41. Markoff RA, Ryan P, and Young T. Endorphins and mood changes in long-distance running. Med Sci Sports Exerc 14: 11-15, 1982.
42. Martin del Campo AF, Dowson JH, Herbert J, and Paykel ES. Effects of naloxone on diurnal rhythms in mood and endocrine function: a dose-response study in man. Psychopharmacology (Berl) 114: 583-590, 1994.
43. Martin del Campo AF, McMurray RG, Besser GM, and Grossman A. Effect of 12-hour infusion of naloxone on mood and cognition in normal male volunteers. Biol Psychiatry 32: 344-353, 1992.
44. Martin-Soelch C, Chevalley AF, Kunig G, Missimer J, Magyar S, Mino A, Schultz W, and Leenders KL. Changes in reward-induced brain activation in opiate addicts. Eur J Neurosci 14: 1360-1368, 2001.
45. Millan MJ. Descending control of pain. Prog Neurobiol 66: 355-474, 2002.
46. Nishimura J, Endo Y, and Kimura F. Increases in cerebral blood flow in rat hippocampus after medial septal injection of naloxone. Stroke 23: 1325-1329, 1992.
47. Ochoa JL, Yarnitsky D, Marchettini P, Dotson R, and Cline M. Interactions between sympathetic vasoconstrictor outflow and C nociceptor-induced antidromic vasodilatation. Pain 54: 191-196, 1993.
48. O'Doherty J, Kringelbach ML, Rolls ET, Hornak J, and Andrews C. Abstract reward and punishment representations in the human orbitofrontal cortex. Nat Neurosci 4: 95-102, 2001.
49. Ozaki S, Narita M, Narita M, Iino M, Sugita J, Matsumura Y, and Suzuki T. Suppression of the morphine-induced rewarding effect in the rat with neuropathic pain: implication of the reduction in mu-opioid receptor functions in the ventral tegmental area. J Neurochem 82: 1192-1198, 2002.
50. Panksepp J, Bean NJ, Bishop P, Vilberg T, and Sahley TL. Opioid blockade and social comfort in chicks. Pharmacol Biochem Behav 13: 673-683, 1980.
51. Papanicolas L, Woolf C, Caneris O, and Borsook D. Dissociation Between the Autonomic Vasoconstrictor Response Following Noxious Heat and Allodynia. Vienna: IASP, 1999.
52. Pasternak GW and Standifer ICM. Mapping of opioid receptors using antisense oligodeoxynucleotides: correlating their molecular biology and pharmacology. Trends Pharmacol Sci 16: 344-350, 1995.
53. Petrovic P, Kalso E, Petersson ICM, and Ingvar M. Placebo and opioid analgesia-imaging a shared neuronal network. Science 295: 1737-1740, 2002.
54. Phelps EA, O'Connor KJ, Gatenby JC, Gore JC, Grillon C, and Davis M. Activation of the left amygdala to a cognitive representation of fear. Nat Neurosci 4: 437-441, 2001.
55. Ploghaus A, Narain C, Beckmann CF, Clare S, Bantick S, Wise R, Matthews PM, Rawlins JN, and Tracey I. Exacerbation of pain by anxiety is associated with activity in a hippocampal network. J Neurosci 21: 9896-98903, 2001.
56. Ploghaus A, Tracey I, Clare S, Gati JS, Rawlins JN, and Matthews PM. Learning about pain: the neural substrate of the prediction error for aversive events. Proc Natl Acad Sci USA 97: 9281-9286, 2000.
57. Price DD, Barrell JJ, and Gracely RH. A psychophysical analysis of experimential factors that selectively influence the affective dimension of pain. Pain 8: 137-149, 1980.
58. Ramsey NF, Gerrits MA, and Van Ree JM. Naltrexone affects cocaine self-administration in naive rats through the ventral tegmental area rather than dopaminergic target regions. Eur Neuropsychopharmacol 9: 93-99, 1999.
59. Ribeiro SJ and De Lima TC. Naloxone-induced changes in tachykinin NK3 receptor modulation of experimental anxiety in mice. Neurosci Lett 258: 155-158, 1998.
60. Ribeiro FC, Scheiber G, and Marichal A. Comparison of time course of neuromuscular blockade in young children following rocuronium and atracurium. Eur J Anaesthesiol 15: 310-313, 1998.
61. Roache JD. Performance and physiological measures in abuse liability evaluation. Br J Addict 86: 1595-1600, 1991.
62. Schad CA, Justice JB Jr, and Holtzman SG. Endogenous opioids in dopaminergic cell body regions modulate amphetamine-induced increases in extracellular dopamine levels in the terminal regions J Pharmacol Exp Ther 300: 932-938, 2002.
63. Schluger JH, Ho A, Borg L, Porter M, Maniar S, Gunduz M, Perret G, King A, and Kreek MJ. Nalmefene causes greater hypothalamic-pituitary-adrenal axis activation than naloxone in normal volunteers: implications for the treatment of alcoholism. Alcohol Clin Exp Res 22: 1430-1436, 1998.
64. Shippenberg TS and Bals-Kubik R. Involvement of the mesolimbic dopamine system in mediating the aversive effects of opioid antagonists in the rat. Behav Pharmacol 6: 99-106, 1995.
65. Shoemaker WJ, Vavrousek-Jakuba E, Arons CD, and Kwok FC. The acquisition and maintenance of voluntary ethanol drinking in the rat: effects of dopaminergic lesions and naloxone. Behav Brain Res 137: 139-148, 2002.
66. Spanagel R, Herz A, and Shippenberg TS. Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. Proc Natl Acad Sci USA 89: 2046-2050, 1992.
67. Stacher G, Abatzi TA, Schulte F, Schneider C, Stacher-Janotta G, Gaupmann G, Mittelbach G, and Steinringer H. Naloxone does not alter the perception of pain induced by electrical and thermal stimulation of the skin in healthy humans. Pain 34: 271-276, 1988.
68. Stolerman IP. Motivational effects of opioids: evidence on the role of endorphins in mediating reward or aversion. Pharmacol Biochem Behav 23: 877-881, 1985.
69. Suzuki Y and Taguchi K. Influence of drugs on evoked potentials in the cat cerebellum. II. Effects of morphine hydrochloride (1). Jpn J Pharmacol 33: 671-679, 1983.
70. Taber MT, Zernig G, and Fibiger HC. Opioid receptor modulation of feeding-evoked dopamine release in the rat nucleus accumbens. Brain Res 785: 24-30, 1998.
71. Tanaka M, Yoshida M, Emoto H, and Ishii H. Noradrenaline systems in the hypothalamus, amygdala and locus coeruleus are involved in the provocation of anxiety: basic studies. Eur J Pharmacol 405: 397-406, 405.
72. Totterdell S and Meredith GE. Topographical organization of projections from the entorhinal cortex to the striatum of the rat. Neuroscience 78: 715-729, 1997.
73. Wigger A and Neumann ID. Endogenous opioid regulation of stress-induced oxytocin release within the hypothalamic paraventricular nucleus is reversed in late pregnancy: a microdialysis study. Neuroscience 112: 121-129, 2002.
74. Willer JC, Le Bars D, and De Broucker T. Diffuse noxious inhibitory controls in man: involvement of an opioidergic link. Eur J Pharmacol 182: 347-355, 1990.
75. Wise RG, Rogers R, Painter D, Bantick S, Ploghaus A, Williams P, Rapeport G, and Tracey I. Combining fMRI with a pharmacokinetic model to determine which brain areas activated by painful stimulation are specifically modulated by remifentanil. Neuroimage 16: 999-1014, 2002.
76. Wolkowitz OM and Tinklenberg JR. Naloxone's effect on cognitive functioning in drug-free and diazepam-treated normal humans. Psychopharmacology 85: 221-223, 1985.
77. Zacny JP, Coalson DW, Lichtor JL, Yajnik S, and Thapar P. Effects of naloxone on the subjective and psychomotor effects of nitrous oxide in humans. Pharmacol Biochem Behav 49: 573-578, 1994.
78. Zubieta JK, Smith YR, Bueller JA, Xu Y, Kilbourn MR, Jewett DM, Meyer CR, Koeppe RA, and Stohler CS. Regional mu opioid receptor regulation of sensory and affective dimensions of pain. Science 293: 311-315, 2001.
79. Zurita A, Martijena I, Cuadra G, Brandao ML, and Molina V. Early exposure to chronic variable stress facilitates the occurrence of anhedonia and enhanced emotional reactions to novel stressors: reversal by naltrexone pretreatment. Behav Brain Res 117: 163-171, 2000.